| (USD) | Sep 2023 | Q/Q |
|---|---|---|
| Revenue | 88.8MM | +6% |
| Gross Profit | 88.6MM | - |
| Cost Of Revenue | 197K | +6% |
| Operating Income | -4.6MM | -35% |
| Operating Expenses | 93.2MM | - |
| Net Income | -2.8MM | -52% |
| R&D | 41.5MM | +11% |
| G&A | 45.4MM | -15% |
| Interest Expense | 1.8MM | -36% |
Short Volume Ratio = Short Volume / All Volume. Source of Short Volume data comes from
FinraMoving Average Convergence/Divergence oscillator (MACD) is one of the simplest and most effective momentum indicators available.
Relative Strength Index (RSI) is a momentum oscillator that measures the speed and change of price movements. RSI oscillates between zero and 100. According to Wilder, RSI is considered overbought when above 70 and oversold when below 30.
Data from two Phase 2 studies in PBC show combination of OCA + bezafibrate achieved biochemical remission (normalization of ALP, total bilirubin, GGT, ALT and AST) in 40-44% of patients in the first 12 weeks OCA 5 or 5-10 mg + bezafibrate 400 mg cohorts in both studies showed a >60% reduction from baseline in serum ALP (primary endpoint) Treatment-emergent adverse events were generally balanced across all cohorts in both studies Data support progression to Phase 3 trials of sustained release for
New analysis demonstrates the impact of OCA on achievement of GGT <3.2×ULN and ALP <1.5×ULN Findings suggest that OCA has the potential to reduce the liver biomarker GGT, in addition to well-known effects on ALP, below thresholds that predict improved outcomes, including survival, in PBC Data to be featured in poster presentation on Monday, November 13 MORRISTOWN, N.J., Nov. 10, 2023 (GLOBE NEWSWIRE) -- Intercept Pharmaceuticals, Inc., a biopharmaceutical company and wholly-owned subsidiary of A
BOLOGNA, Italy and MORRISTOWN, N.J., Nov. 08, 2023 (GLOBE NEWSWIRE) -- Alfasigma S.p.A. (“Alfasigma”) and Intercept Pharmaceuticals, Inc. (“Intercept”) announced today the completion of the acquisition of Intercept by Alfasigma through its wholly owned subsidiary Interstellar Acquisition Inc. Following the completion of Alfasigma’s successful tender offer to purchase all outstanding shares of common stock of Intercept for USD 19.00 per share, net to the seller thereof in cash, without interest,
Intercept (ICPT) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
In rough markets it’s important to keep and eye out for overbought stocks. Finding the right timing to buy and sell stocks will always be a sought-after skill by any investor searching for that holy grail. While I do believe that there isn’t one, I firmly believe that overbought stocks still provide signs of when there is a potential risk of an implosion of buyers or sellers.InvestorPlace - Stock Market News, Stock Advice & Trading Tips For example, when stocks move sharply upwards, so do the ch
It is a pleasure to report that the Intercept Pharmaceuticals, Inc. ( NASDAQ:ICPT ) is up 67% in the last quarter. But...
Madrigal (MDGL) is raising funds through a public offering of 1.25 million shares of its common stock to use in commercial activities in the preparation of a potential launch of resmetirom in the United States.
Acquisition news from Intercept (ICPT) and study updates from Immunovant (IMVT) are in focus in the biotech sector.
Intercept Pharmaceuticals (ICPT) gains an acquisition deal from Alfasigma for $19.00 per share in cash.
Intercept (ICPT) was a big mover last session on higher-than-average trading volume. The latest trend in earnings estimate revisions might not help the stock continue moving higher in the near term.